FDA Okays At-Home Starting Dose for Lecanemab in Early AD

The FDA has approved at-home subcutaneous dosing for lecanemab (Leqembi Iqlik), an Alzheimer's antibody, allowing patients to self-administer or have caregivers administer the starting dose—the first time this disease-modifying treatment can be initiated outside clinical settings. This shift from intravenous to subcutaneous administration removes a major access barrier and enables combination therapy models as the field moves beyond single-drug treatment.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.